Biomagnetics Diagnostics Corporation Announces LOI to Acquire Lanzhou Roya Biotechnology Co., Ltd.-First of Several Acquisitions Targeted at $1.00 BMGP Share Valuation

SAN FRANCISCO--(BUSINESS WIRE)--Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP - News) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Lanzhou Sanhuan New Technology Development Ltd. of Ganzu, China. This expected acquisition is the first of several planned acquisitions targeted at a $1.00 share price for Biomagnetics Diagnostics’ common shares. Biomagnetics plans to rapidly transition the trading of its shares to the OTCBB upon the expected completion of its full audit and financial review, which is targeted for release within the next few weeks.